کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1335356 979526 2007 12 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH22+)[PtCl6]·H2Oand(RosH22+)2[PtCl6]Cl2·4H2O
موضوعات مرتبط
مهندسی و علوم پایه شیمی شیمی معدنی
پیش نمایش صفحه اول مقاله
The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH22+)[PtCl6]·H2Oand(RosH22+)2[PtCl6]Cl2·4H2O
چکیده انگلیسی

A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [PtIV(LH+)Cl5] (1–14), where LH+ stands for protonated form of the Bap derivative (1–12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared.They have been fully characterized by microanalysis, conductivity, FT-IR, 1H, 13C, 15N and 195Pt NMR and ES+ mass spectroscopy.It has been found that the cytokinin molecule is coordinated via N9 atom to platinum(IV) and N1, N7-protonated in case of complexes 1–12, and N7 coordinated and N1-protonated in case of complexes with CDK inhibitors (13 and 14).Predicted molecular geometries of the complexes have been supported by DFT calculations at the B3LYP level with the 6-311+G∗∗/LANL2DZ and aug-cc-pVDZ/LANL2DZ basis sets.All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7).The best result has been achieved for complex 14, where IC50 = 17 μM against K562. The molecular structures of two ionic pair compounds (BohH22+)[PtCl6]·H2O(15)and(RosH22+)2[PtCl6]Cl2·4H2O(16) have been determined by a single crystal X-ray analysis.

A series of the first Pt(IV) complexes, involving a protonated form of cytokinin or CDK-inhibitor (Bohemine or Roscovitine) derived from 6-benzylaminopurine, of the type [PtIV(LH+)Cl5] (1–14) {where LH+ stands for the protonated form of the organic molecule} have been prepared and fully characterized by different physical methods.Geometries of representative complexes have been optimized by DFT calculations.The molecular structures of (BohH22+)[PtCl6]·H2O(15)and(RosH22+)2[PtCl6]Cl2·4H2O(16) have been determined by a single X-ray analysis.The complexes have been also screened in vitro for their cytotoxicity against selected human cancer cell lines.Figure optionsDownload as PowerPoint slide

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Polyhedron - Volume 26, Issue 18, 20 November 2007, Pages 5271–5282
نویسندگان
, , , , ,